{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:20:30Z","timestamp":1783574430537,"version":"3.55.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Aurum Ventures ltd, Rama Gan, Israel"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.ejpb.2018.10.013","type":"journal-article","created":{"date-parts":[[2018,10,18]],"date-time":"2018-10-18T17:52:27Z","timestamp":1539885147000},"page":"214-223","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Pharmacodynamical effects of orally administered exenatide nanoparticles embedded in gastro-resistant microparticles"],"prefix":"10.1016","volume":"133","author":[{"given":"Liat","family":"Soudry-Kochavi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalya","family":"Naraykin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanna","family":"Di Paola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Gugliandolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Peritore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6131-3690","authenticated-orcid":false,"given":"Salvatore","family":"Cuzzocrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehud","family":"Ziv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taher","family":"Nassar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Benita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2018.10.013_b0005","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jsps.2014.06.004","article-title":"A review on the strategies for oral delivery of proteins and peptides and their clinical perspectives","volume":"24","author":"Muheem","year":"2016","journal-title":"Saudi Pharm. J."},{"key":"10.1016\/j.ejpb.2018.10.013_b0010","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrd2399","article-title":"Protein therapeutics: a summary and pharmacological classification","volume":"7","author":"Leader","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejpb.2018.10.013_b0015","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.drudis.2009.10.009","article-title":"Synthetic therapeutics peptides: science and market","volume":"15","author":"Vlieghe","year":"2010","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejpb.2018.10.013_b0020","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.drudis.2014.10.003","article-title":"Peptide therapeutics: current status and future directions","volume":"20","author":"Fosgerau","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejpb.2018.10.013_b0025","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.4155\/tde.13.104","article-title":"Basics and recent advances in peptide and protein drug delivery","volume":"4","author":"Bruno","year":"2013","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.ejpb.2018.10.013_b0030","doi-asserted-by":"crossref","first-page":"269","DOI":"10.4103\/0250-474X.42967","article-title":"Protein and peptide drug delivery: oral approaches","volume":"70","author":"Shaji","year":"2008","journal-title":"Indian Pharm. Sci."},{"key":"10.1016\/j.ejpb.2018.10.013_b0035","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3109\/10717544.2013.819611","article-title":"Oral delivery of therapeutic proteins and peptides: a review on recent developments","volume":"20","author":"Gupta","year":"2013","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejpb.2018.10.013_b0040","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0939-6411(00)00084-9","article-title":"Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake?","volume":"50","author":"Jung","year":"2000","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2018.10.013_b0045","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/nrd1828","article-title":"Exenatide","volume":"4","author":"Davidson","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejpb.2018.10.013_b0050","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1089\/dia.2011.0050","article-title":"Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes","volume":"13","author":"De-Young","year":"2011","journal-title":"Diabetes Technol. Ther."},{"key":"10.1016\/j.ejpb.2018.10.013_b0055","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3109\/10717544.2013.871760","article-title":"Pharmacokinetics, in-vitro and in-vivo correlation and efficacy of exenatide microspheres in diabetic rats","volume":"22","author":"Li","year":"2015","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejpb.2018.10.013_b0060","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(08)61206-4","article-title":"Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomized, open-label, non-inferiority study","volume":"372","author":"Drucker","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ejpb.2018.10.013_b0065","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jdiacomp.2013.12.009","article-title":"Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes","volume":"28","author":"Henry","year":"2014","journal-title":"J. Diabetes Complicat."},{"key":"10.1016\/j.ejpb.2018.10.013_b0070","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jconrel.2015.09.012","article-title":"Improved oral absorption of exenatide using an original nanoencapsulation and microencapsulation approach","volume":"217","author":"Soudry-Kochavi","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2018.10.013_b0075","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1067\/mlc.2002.126504","article-title":"Altered red cell turnover in diabetic mice","volume":"140","author":"Manodori","year":"2002","journal-title":"J. Lab. Clin. Med."},{"key":"10.1016\/j.ejpb.2018.10.013_b0080","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/bcp.12698","article-title":"Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppresion to octreotide LAR in healthy volunteers","volume":"80","author":"Tiberg","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2018.10.013_b0085","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1359\/jbmr.2002.17.8.1478","article-title":"Bioavilability and biological efficacy of a new oral formulation of salmon calcitonin in healthy volunteers","volume":"17","author":"Buclin","year":"2002","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.ejpb.2018.10.013_b0090","first-page":"498","article-title":"Liraglutide (Victoza): the first incretin mimetic injection for type 2-dianetes","volume":"35","author":"Jackson","year":"2010","journal-title":"P.T."},{"key":"10.1016\/j.ejpb.2018.10.013_b0095","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1080\/14656566.2017.1282463","article-title":"Exenaitde: pharmacokinetics, clinical use and future directions","volume":"18","author":"Knop","year":"2017","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.ejpb.2018.10.013_b0100","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ijpharm.2008.01.015","article-title":"Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration","volume":"356","author":"Gedulin","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2018.10.013_b0105","first-page":"827","article-title":"Pharmacokinetics and pharmacodynamics of insulin an analogs in special populations with type 2 diabetes mellitus","volume":"4","author":"Morello","year":"2014","journal-title":"Int. J. Gen. Med."},{"key":"10.1016\/j.ejpb.2018.10.013_b0110","first-page":"1972","article-title":"Enhanced oral bioavailability of insulin-loaded solid lipid nanoparticles: pharmacokinetic bioavailability of insulin-loaded solid lipid nanoparticles in diabetic rats","volume":"23","author":"Ansari","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejpb.2018.10.013_b0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6904-7-10","article-title":"Pharmacokinetics of recombinant human growth hormone administered by cool.click 2, a new needle-free device, compared with subcutaneous administration using a conventional syringe and needle","volume":"7","author":"Brearley","year":"2007","journal-title":"BMC Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2018.10.013_b0120","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1002\/jps.24215","article-title":"Improved oral bioavailability of human growth hormone by a combination of liposomes containing bio-enhancers and tetraether lipids and omeprazole","volume":"103","author":"Parmentier","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2018.10.013_b0125","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1177\/0091270004273321","article-title":"Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein","volume":"45","author":"Zhou","year":"2005","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2018.10.013_b0130","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2174\/157339913804143225","article-title":"Regulation of insulin synthesis and secretion and pancreatic Beta-cell dysfunction in diabetes","volume":"9","author":"Fu","year":"2013","journal-title":"Curr. Diabetes Rev."},{"key":"10.1016\/j.ejpb.2018.10.013_b0135","first-page":"189","article-title":"The challenge of patient adherence","volume":"1","author":"Martin","year":"2005","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.ejpb.2018.10.013_b0140","unstructured":"World Health Organization, Diabetes Key facts, <http:\/\/www.who.int\/mediacentre\/factsheets\/fs312\/en\/> (accessed 15 November 2017)."},{"key":"10.1016\/j.ejpb.2018.10.013_b0145","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.2147\/PPA.S106821","article-title":"Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors","volume":"10","author":"Polonsky","year":"2016","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.ejpb.2018.10.013_b0150","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/j.clinthera.2016.05.009","article-title":"Self-reported barriers to adherence and persistence to treatment with injectable medications for type 2 diabetes","volume":"38","author":"Spain","year":"2016","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ejpb.2018.10.013_b0155","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.biotechadv.2014.07.006","article-title":"A review of advanced oral drug delivery technologies facilitating the protection and absorption of protein and peptides molecules","volume":"15","author":"Choonara","year":"2014","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.ejpb.2018.10.013_b0160","first-page":"s1","article-title":"Standards of medical care in diabetes-2017","volume":"40","author":"American Diabetes Association","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejpb.2018.10.013_b0165","unstructured":"American Diabetes Association, Standards of medical care in diabetes \u2013 2018 abridged for primary care providers 36 (2018) 14\u201337."},{"key":"10.1016\/j.ejpb.2018.10.013_b0170","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejim.2010.07.008","article-title":"The oral glucose tolerance test (OGTT) revisited","volume":"22","author":"Bartoli","year":"2011","journal-title":"Eur. J. Interm. Med."},{"key":"10.1016\/j.ejpb.2018.10.013_b0175","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1242\/dmm.006239","article-title":"Standard operating procedures for describing and performing metabolic tests of glucose homeostasis in mice","volume":"3","author":"Ayala","year":"2010","journal-title":"Dis. Model Mech."},{"key":"10.1016\/j.ejpb.2018.10.013_b0180","first-page":"76","article-title":"Current status of the oral delivery of insulin","volume":"25","author":"Agrawal","year":"2001","journal-title":"Pharm. Technol."},{"key":"10.1016\/j.ejpb.2018.10.013_b0185","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jconrel.2018.03.018","article-title":"In vivo evaluation of an oral self-emulsifying drug delivery system (SEEDS) for exenatide","volume":"277","author":"Menzel","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2018.10.013_b0190","first-page":"e62","article-title":"Choice of therapy in patients with type 2 diabetes inadequately controlled with metformin and a sulphonylurea: a systemic review and mixed-treatment comparison meta-analysis","volume":"6","author":"Mclntosh","year":"2012","journal-title":"Open Med."},{"key":"10.1016\/j.ejpb.2018.10.013_b0195","unstructured":"World Health Organization, Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus, <www.who.int\/diabetes\/publications\/report-hba1c_2011.pdf> (accessed 2011)."},{"key":"10.1016\/j.ejpb.2018.10.013_b0200","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1007\/s11892-014-0548-3","article-title":"Beyond HbA1c and glucose: the role of nontraditional glycemic markers in diabetes diagnosis, prognosis and management","volume":"14","author":"Parrinello","year":"2014","journal-title":"Curr. Diab. Rep."},{"key":"10.1016\/j.ejpb.2018.10.013_b0205","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study","volume":"321","author":"Stratton","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.ejpb.2018.10.013_b0210","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2017.14752","article-title":"Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial","volume":"318","author":"Davies","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.ejpb.2018.10.013_b0215","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J. Basic Clin. Pharm."},{"key":"10.1016\/j.ejpb.2018.10.013_b0220","doi-asserted-by":"crossref","first-page":"14804","DOI":"10.1073\/pnas.93.25.14804","article-title":"Correction of obesity and diabetes in genetically obese mice by leptin gene therapy","volume":"93","author":"Muzzin","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejpb.2018.10.013_b0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nutd.2011.21","article-title":"Appetite regulation and weight control: the role of gut hormones","volume":"2","author":"Perry","year":"2012","journal-title":"Nutr. Diabetes"},{"key":"10.1016\/j.ejpb.2018.10.013_b0230","series-title":"Peptides Applications in Biomedicime, Biotechnology and Bioengineering","first-page":"24","article-title":"Synthetic approaches of naturally and rationally designed peptides and peptidomimetics","author":"Lobo-Ruiz","year":"2017"},{"key":"10.1016\/j.ejpb.2018.10.013_b0235","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0083-6729(08)00602-X","article-title":"The structure and function of insulin: decoding the TR transition","volume":"80","author":"Weiss","year":"2009","journal-title":"Vitam. Horm."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641118308944?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641118308944?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,17]],"date-time":"2018-11-17T03:10:10Z","timestamp":1542424210000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641118308944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":47,"alternative-id":["S0939641118308944"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2018.10.013","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacodynamical effects of orally administered exenatide nanoparticles embedded in gastro-resistant microparticles","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2018.10.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}